Skip to search formSkip to main contentSkip to account menu

IDO Inhibitor NLG919

Known as: GDC-0919, NLG-919, NLG919 
An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the… 
Highly Cited
2018
Highly Cited
2018
Checkpoint blockade immunotherapy is promising for clinical treatment of various malignant tumors. However, checkpoint blockade… 
Highly Cited
2018
Highly Cited
2018
Combination therapeutic regimen is becoming a primary direction for current cancer immunotherapy to broad the antitumor response… 
Highly Cited
2018
Highly Cited
2018
BackgroundIndoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible… 
Review
2017
Review
2017
Over the last decade, tryptophan catabolism has been firmly established as a powerful mechanism of innate and adaptive immune… 
Highly Cited
2017
Highly Cited
2017
To achieve synergistic therapeutic efficacy and prevent cancer relapse, chemotherapy and immunotherapy have been combined as a… 
Review
2015
Review
2015
Indoleamine 2, 3-dioxygenase 1 (IDO1), IDO2, and tryptophan 2, 3-dioxygenase (TDO) comprise a family of enzymes that catalyze the… 
Highly Cited
2013
Highly Cited
2013
The IDO pathway mediates immunosuppressive effects through the metabolization of tryptophan (Trp) to kynurenine (Kyn), triggering…